Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

(2012) L Robertson et al.   BRITISH JOURNAL OF CANCER

Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

(2011) E. Comen et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

(2011) Anne-Renee Hartman et al.   CANCER

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

(2010) Janice S. Kwon et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

(2010) Mark E. Robson et al.   JOURNAL OF CLINICAL ONCOLOGY

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer

(2009) Michael J. Hall et al.   CANCER